An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.


Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Estée Lauder Sues Jo Malone Over Trademark Dispute Involving Zara
U.S. Futures Slide as Oil Prices Surge on Middle East Shipping Attacks
Oil Prices Surge Toward $100/Barrel After Tanker Attacks in Iraqi Waters
Adobe CEO Shantanu Narayen Steps Down After 18 Years as Company Beats Q1 Earnings
Anduril Industries Acquires ExoAnalytic Solutions to Bolster Space Defense Capabilities
China Escalates BHP Iron Ore Ban Amid Contract Dispute
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes
Meta Delays 'Avocado' AI Model Release After Falling Short of Rivals
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Stryker Cyberattack Disrupts Operations Amid Iran-Linked Hacking Claims
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
USMCA Reaffirmed as Canada and Mexico Push Back Against U.S. Bilateral Trade Signals
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
ByteDance Expands AI Cloud Infrastructure Using NVIDIA Blackwell Chips in Southeast Asia
Morgan Stanley Limits Withdrawals at Private Credit Fund Amid Market Turmoil 



